The Impact of Low-Dose Esketamine Combined With Ciprofol on the Quality of Early Postoperative Recovery Among Elderly Patients Undergoing Painless Gastroscopy
NCT ID: NCT06617039
Last Updated: 2025-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
376 participants
INTERVENTIONAL
2024-10-10
2025-07-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Esketamine Combined With Different General Anesthetics on Quality of Postoperative Recovery
NCT06976996
Effect of Low-dose Esketamine Combined With Target-controlled Infusion of Propofol for Painless Gastrointestinal Endoscopy
NCT04691076
Combined Use of Etomidate and Propofol in Painless Gastroscopy.
NCT01913054
Effect of Subanesthetic Dose of Esketamine on Sleep Quality and Recovery of Gastrointestinal Function in Patients Undergoing General Anesthesia Laparoscopic Uterine Surgery in the Early Postoperative Period
NCT05715671
Impact of Frailty on Nalbuphine Dose for Postoperative Analgesia in Elderly Patients Undergoing Laparoscopic GI Surgery
NCT06953570
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ciprofol group (C group)
Ciprofol group will be started with ciprofol 0.2-0.4 mg/kg.
Ciprofol
Ciprofol group will be started with ciprofol 0.2-0.4 mg/kg.
The group of remifentanil 0.5ug/kg combined with ciprofol(R group)
R group will be started with remifentanil 0.5ug/kg and ciprofol 0.2-0.4 mg/kg.
Remifentanil and ciprofol
R group will be started with remifentanil 0.5ug/kg and ciprofol 0.4 mg/kg.
The group of esketamine 0.3mg/kg combined with ciprofol(E1 group)
E1 group will be started with esketamine 0.3mg/kg and ciprofol 0.2-0.4 mg/kg.
esketamine 0.3mg/kg and ciprofol
Anesthesia induction was initiated by esketamine 0.3mg/kg, followed by ciprofol 0.2-0.4mg/kg.
The group of esketamine 0.5mg/kg combined with ciprofol(E2 group)
E2 group will be started with esketamine 0.5mg/kg and ciprofol 0.2-0.4 mg/kg.
esketamine 0.5mg/kg and ciprofol
Anesthesia induction was initiated by esketamine 0.5mg/kg, followed by ciprofol 0.2-0.4mg/kg.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Remifentanil and ciprofol
R group will be started with remifentanil 0.5ug/kg and ciprofol 0.4 mg/kg.
esketamine 0.3mg/kg and ciprofol
Anesthesia induction was initiated by esketamine 0.3mg/kg, followed by ciprofol 0.2-0.4mg/kg.
esketamine 0.5mg/kg and ciprofol
Anesthesia induction was initiated by esketamine 0.5mg/kg, followed by ciprofol 0.2-0.4mg/kg.
Ciprofol
Ciprofol group will be started with ciprofol 0.2-0.4 mg/kg.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2\. Age 60-75 years old
3\. ASA grade Ⅰ-Ⅱ
4\. The respiratory tract is unobstructed and there is no difficult airway
5\. No history of allergy to etomidate and cyclopropofol
6\. Participants with normal heart, liver, lung, and kidney functions
7\. Able to complete the QoR-15, MMSE, and HADS scale assessments
8\. lnformed consent, voluntary participation in the trial, and signed by the patient informed consent
Exclusion Criteria
2\. Participants with a history of mental illness and abuse of sedative drugs
3\. Participants with allergies or contraindications to the study drugs
4\. Participants with severe visual, auditory, or speech communication impairments
5\. Participants with acute gastrointestinal inflammation or obstruction
6\. History of uncontrolled diabetes, hypertension, and hypotension
7\. Participants with malignant tumors, severe hyperkalemia, bronchial asthma, or excessive obesity (BMI \> 30kg/m2)
8\. Participants with aneurysmal vascular diseases of the thoracic and abdominal aorta, intracranial and peripheral arterial vessels.
9\. Unable to cooperate with the QoR-15, MMSE, and HADS scale assessments
60 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Northern Jiangsu People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ju Gao
Study Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Subei People's Hospital of Jiangsu Province
Yangzhou, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024ky251
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.